10-KPeriod: FY2014

BRISTOL MYERS SQUIBB CO Annual Report, Year Ended Dec 31, 2014

Filed February 13, 2015For Securities:BMYCELG-RIBMYMP

Summary

Bristol-Myers Squibb (BMY) in its 2014 10-K filing presents a company undergoing significant strategic transformation. The company is actively divesting non-core assets, notably its diabetes business, while concurrently pursuing acquisitions and licensing agreements to bolster its pipeline in key therapeutic areas. These areas include oncology, virology, immunology, specialty cardiovascular disease, fibrosis, and genetically defined diseases. This strategic shift aims to focus resources on high-growth opportunities and deliver innovative medicines to address unmet medical needs, positioning BMY as a leading-edge biopharmaceutical company. Financial performance for 2014 showed a slight decrease in total revenues to $15.9 billion from $16.4 billion in 2013, with the United States remaining the largest market but seeing a decline in its revenue percentage. The company's product portfolio is heavily reliant on patent exclusivity, with key products like Abilify and Sustiva facing impending patent expirations in major markets. However, the report also highlights promising growth in newer products such as Eliquis and Opdivo, which are expected to drive future revenue streams. Investors should monitor patent cliffs and the success of the company's new product launches and R&D pipeline.

Financial Highlights

56 data points
Beta

Revenue

$15.88B

75.2% Gross Margin

Net Income

$2.00B

12.6% Net Margin

EPS (Diluted)

$1.20

Total Assets

$33.75B

Cash & Equivalents

$5.57B

Free Cash Flow

$2.62B

Financial Statements
Beta
Revenue$15.88B
Cost of Revenue$3.93B
Gross Profit$11.95B
R&D Expenses$4.53B
SG&A Expenses$4.82B
Operating Expenses$13.50B
Interest Expense$203.00M
Net Income$2.00B
EPS (Basic)$1.21
EPS (Diluted)$1.20
Shares Outstanding (Basic)1.66B
Shares Outstanding (Diluted)1.67B

Key Highlights

  • 1BMY is strategically divesting non-core businesses (e.g., diabetes) and acquiring/licensing assets to focus on key therapeutic areas: oncology, virology, immunology, specialty cardiovascular, fibrosis, and genetically defined diseases.
  • 2Total revenues for 2014 were $15.9 billion, a slight decrease from $16.4 billion in 2013.
  • 3The United States remains the largest revenue-generating region (49% in 2014), though its contribution has decreased over the past three years.
  • 4Key products like Abilify ($2.02B revenue, exclusivity loss in 2015 in US, 2014 in EU) and Sustiva Franchise ($1.44B revenue, exclusivity loss in 2017 in US) face significant patent cliffs.
  • 5Newer products show strong growth potential, with Eliquis revenue increasing significantly to $774 million in 2014 and Opdivo, a promising oncology drug, generating $6 million in early revenue with future exclusivity until 2027 (US) and 2026 (China).
  • 6The company relies heavily on patent protection and regulatory exclusivity for its innovative products, with substantial revenue declines often occurring upon the loss of exclusivity.
  • 7BMY is investing in its R&D pipeline and new product launches to offset potential revenue shortfalls from expiring patents.

Frequently Asked Questions

BMY's core strategy is to transform into a leading-edge biopharmaceutical company focused on discovering, developing, and delivering innovative medicines. This involves divesting non-core assets like the diabetes business and concentrating resources on key therapeutic areas such as oncology, virology, immunology, specialty cardiovascular disease, fibrosis, and genetically defined diseases through acquisitions, licensing, and internal R&D.

Several key products are nearing the end of their market exclusivity. Abilify, a significant revenue driver ($2.02B in 2014), lost exclusivity in Europe in 2014 and is set to lose it in the US in 2015. The Sustiva Franchise ($1.44B in 2014) is estimated to lose US exclusivity in 2017. The loss of exclusivity for these products can lead to substantial and rapid declines in sales due to generic competition.

Growth is expected to come from newer products and the company's strengthened R&D pipeline. Eliquis, a cardiovascular drug, showed significant revenue growth in 2014 ($774M). Opdivo, an innovative oncology treatment, is in its early stages but has strong future exclusivity protection and represents a key growth opportunity. The company's focus on core therapeutic areas and strategic acquisitions aims to build a robust portfolio of innovative medicines.

While the United States remains the largest market (49% of revenues in 2014), its share has been declining over the past few years (51% in 2013, 59% in 2012). Europe represents the second-largest market (23% in 2014), followed by Japan (6%) and China (4%). This indicates a slight shift in revenue concentration away from the US and towards other international markets.